Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma,

Caitlin L. Costello, MD, Peter Holman, MD, Margarida de Magalhaes-Silverman, MD, Sue Corringham, R.N., Januario E. Castro, M.D., Edward D. Ball, M.D.

Blood (2011) 118 (21): 4036.

https://doi.org/10.1182/blood.V118.21.4036.4036

Published: 2011

Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC

Blood (2011) 118 (21): 1605.

https://doi.org/10.1182/blood.V118.21.1605.1605

Published: 2011

Journal Articles

Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Adult Patients with Non-Hematologic Malignancies

Mitchell E. Horwitz, MD, Edward Gorak, Peter Holman, MD, Edward Libby, MD, Dirk Huebner, MD, Purvi D Mody, PhD, Jeffrey R. Schriber, MD

Blood (2010) 116 (21): 2249.

https://doi.org/10.1182/blood.V116.21.2249.2249

Published: 2010

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, John Bender, PharmD

Blood (2007) 110 (11): 2567.

https://doi.org/10.1182/blood.V110.11.2567.2567

Published: 2007

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD

Blood (2006) 108 (11): 691.

https://doi.org/10.1182/blood.V108.11.691.691

Published: 2006

Journal Articles

BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin’s Lymphoma and Hodgkin’s Disease: A Single Center Comparative Study of 219 Patients.

Asad Bashey, MD, PhD, Oralia Loza, Bridget Medina, Katherine Keesee, PharmD, Sue Corringham, RN, Januario Castro, MD, Peter Holman, MD, Thomas A. Lane, MD, Edward D. Ball, MD, Ewa Carrier, MD

Blood (2005) 106 (11): 2079.

https://doi.org/10.1182/blood.V106.11.2079.2079

Published: 2005

Journal Articles

Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF: An Efficient and Predictable PBPC Mobilization Regimen for Autografting: A Single Center Study of Two Hundred and Thirty Patients.

Thomas A. Lane, MD, Lin Liu, PhD, Anita Ihasz, Bridget Medina, Sue Corringham, RN, Peter Holman, MD, Ewa Carrier, MD, Januario Castro, MD, Edward D. Ball, MD, Asad Bashey, MD

Blood (2005) 106 (11): 5281.

https://doi.org/10.1182/blood.V106.11.5281.5281

Published: 2005

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

Journal Articles

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, John F. Bender, PharmD

Blood (2004) 104 (11): 587.

https://doi.org/10.1182/blood.V104.11.587.587

Published: 2004

NARROW

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma,

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Adult Patients with Non-Hematologic Malignancies

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin’s Lymphoma and Hodgkin’s Disease: A Single Center Comparative Study of 219 Patients.

Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF: An Efficient and Predictable PBPC Mobilization Regimen for Autografting: A Single Center Study of Two Hundred and Thirty Patients.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only